Engelmann D - Search Results

1

Hybrid modeling of the crosstalk between signaling and transcriptional networks using ordinary differential equations and multi-valued logic.

Khan FM, Schmitz U, Nikolov S, Engelmann D, Pützer BM, Wolkenhauer O, Vera J. Khan FM, et al. Among authors: engelmann d. Biochim Biophys Acta. 2014 Jan;1844(1 Pt B):289-98. doi: 10.1016/j.bbapap.2013.05.007. Epub 2013 May 18. Biochim Biophys Acta. 2014. PMID: 23692959

2

Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network.

Vera J, Schmitz U, Lai X, Engelmann D, Khan FM, Wolkenhauer O, Pützer BM. Vera J, et al. Among authors: engelmann d. Cancer Res. 2013 Jun 15;73(12):3511-24. doi: 10.1158/0008-5472.CAN-12-4095. Epub 2013 Feb 27. Cancer Res. 2013. PMID: 23447575

3

Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.

Engelmann D, Pützer BM. Engelmann D, et al. Drug Resist Updat. 2010 Aug-Oct;13(4-5):119-31. doi: 10.1016/j.drup.2010.06.001. Epub 2010 Aug 1. Drug Resist Updat. 2010. PMID: 20675184 Review.

4

Emerging from the shade of p53 mutants: N-terminally truncated variants of the p53 family in EMT signaling and cancer progression.

Engelmann D, Pützer BM. Engelmann D, et al. Sci Signal. 2014 Sep 30;7(345):re9. doi: 10.1126/scisignal.2005699. Sci Signal. 2014. PMID: 25270260 Review.

5

Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures.

Wang Y, Alla V, Goody D, Gupta SK, Spitschak A, Wolkenhauer O, Pützer BM, Engelmann D. Wang Y, et al. Among authors: engelmann d. Nucleic Acids Res. 2016 Jan 8;44(1):117-33. doi: 10.1093/nar/gkv885. Epub 2015 Sep 8. Nucleic Acids Res. 2016. PMID: 26350215 Free PMC article.

6

Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures.

Khan FM, Marquardt S, Gupta SK, Knoll S, Schmitz U, Spitschak A, Engelmann D, Vera J, Wolkenhauer O, Pützer BM. Khan FM, et al. Among authors: engelmann d. Nat Commun. 2017 Aug 4;8(1):198. doi: 10.1038/s41467-017-00268-2. Nat Commun. 2017. PMID: 28775339 Free PMC article.

7

Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers.

Goody D, Gupta SK, Engelmann D, Spitschak A, Marquardt S, Mikkat S, Meier C, Hauser C, Gundlach JP, Egberts JH, Martin H, Schumacher T, Trauzold A, Wolkenhauer O, Logotheti S, Pützer BM. Goody D, et al. Among authors: engelmann d. Theranostics. 2019 Feb 20;9(5):1490-1509. doi: 10.7150/thno.29546. eCollection 2019. Theranostics. 2019. PMID: 30867845 Free PMC article.

8

E2F1 apoptosis counterattacked: evil strikes back.

Pützer BM, Engelmann D. Pützer BM, et al. Among authors: engelmann d. Trends Mol Med. 2013 Feb;19(2):89-98. doi: 10.1016/j.molmed.2012.10.009. Epub 2012 Dec 5. Trends Mol Med. 2013. PMID: 23219173 Review.

9

Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death.

Engelmann D, Knoll S, Ewerth D, Steder M, Stoll A, Pützer BM. Engelmann D, et al. Cell Mol Life Sci. 2010 Mar;67(6):931-48. doi: 10.1007/s00018-009-0222-0. Epub 2009 Dec 15. Cell Mol Life Sci. 2010. PMID: 20013022 Free PMC article.

10

The dark side of E2F1: in transit beyond apoptosis.

Engelmann D, Pützer BM. Engelmann D, et al. Cancer Res. 2012 Feb 1;72(3):571-5. doi: 10.1158/0008-5472.CAN-11-2575. Cancer Res. 2012. PMID: 22298593 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters